Akari Therapeutics

Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company based in London, United Kingdom, dedicated to developing and commercializing treatments for rare and orphan autoimmune and inflammatory diseases. The company's lead product candidate, Nomacopan, is a second-generation complement inhibitor that targets the complement component 5 (C5) and leukotriene B4 (LTB4) pathways, playing a crucial role in disease progression. Nomacopan is currently being evaluated in clinical trials for several conditions, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, bullous pemphigoid, and thrombotic microangiopathy. Akari Therapeutics is committed to addressing unmet medical needs in these areas through innovative therapeutic solutions.

Wendy DiCicco

Interim CFO

1 past transactions

Peak Bio

Acquisition in 2024
Peak Bio is a clinical-stage biopharmaceutical company dedicated to developing therapeutics for oncology, inflammatory diseases, and rare conditions. The company aims to address significant unmet medical needs through its innovative drug development efforts. By focusing on these critical areas, Peak Bio seeks to advance treatment options and improve patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.